IS2599B - 3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess - Google Patents

3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess

Info

Publication number
IS2599B
IS2599B IS7470A IS7470A IS2599B IS 2599 B IS2599 B IS 2599B IS 7470 A IS7470 A IS 7470A IS 7470 A IS7470 A IS 7470A IS 2599 B IS2599 B IS 2599B
Authority
IS
Iceland
Prior art keywords
phenylsulfonyl
piperazin
quinoline
pharmaceutically acceptable
acceptable derivatives
Prior art date
Application number
IS7470A
Other languages
English (en)
Other versions
IS7470A (is
Inventor
Mahmood Ahmed
Christopher Norbert Johnson
Martin C Jones
Gregor James Macdonald
Stephen Frederick Moss
Mervyn Thompson
Charles Edward Wade
David Witty
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28456035&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2599(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0207289A external-priority patent/GB0207289D0/en
Priority claimed from GB0225678A external-priority patent/GB0225678D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IS7470A publication Critical patent/IS7470A/is
Publication of IS2599B publication Critical patent/IS2599B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IS7470A 2002-03-27 2004-09-24 3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess IS2599B (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0207289A GB0207289D0 (en) 2002-03-27 2002-03-27 Novel compounds
GB0225678A GB0225678D0 (en) 2002-11-04 2002-11-04 Novel compounds
PCT/EP2003/003197 WO2003080580A2 (en) 2002-03-27 2003-03-25 Quinoline derivatives and their use as 5-ht6 ligands

Publications (2)

Publication Number Publication Date
IS7470A IS7470A (is) 2004-09-24
IS2599B true IS2599B (is) 2010-04-15

Family

ID=28456035

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7470A IS2599B (is) 2002-03-27 2004-09-24 3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess

Country Status (27)

Country Link
US (5) US7452888B2 (is)
EP (2) EP1497266B1 (is)
JP (2) JP4455064B2 (is)
KR (1) KR101020399B1 (is)
CN (1) CN1315809C (is)
AR (1) AR039127A1 (is)
AT (1) ATE398108T1 (is)
AU (1) AU2003219103B2 (is)
BR (1) BRPI0308696B8 (is)
CA (1) CA2479786C (is)
CY (2) CY1108313T1 (is)
DE (1) DE60321558D1 (is)
DK (2) DK1497266T3 (is)
ES (2) ES2386828T3 (is)
IL (2) IL164108A0 (is)
IS (1) IS2599B (is)
MX (1) MXPA04009318A (is)
MY (1) MY138836A (is)
NO (1) NO329319B1 (is)
NZ (1) NZ535239A (is)
PL (1) PL209872B1 (is)
PT (2) PT1956004E (is)
RU (1) RU2309154C9 (is)
SI (2) SI1497266T1 (is)
TW (1) TWI268928B (is)
WO (1) WO2003080580A2 (is)
ZA (1) ZA200407320B (is)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7452888B2 (en) * 2002-03-27 2008-11-18 Glaxo Group Limited Quinoline derivatives and their use as 5-ht6 ligands
CN100482662C (zh) 2003-02-14 2009-04-29 惠氏公司 作为5-羟基色胺-6配体的杂环基-3-磺酰基氮杂吲哚或-氮杂吲唑衍生物
WO2004074243A2 (en) 2003-02-14 2004-09-02 Wyeth Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
BRPI0412263B1 (pt) 2003-07-22 2019-10-15 Arena Pharmaceuticals, Inc. Derivados de diaril e aril heteroaril uréia, uso e composição farmacêutica contendo os mesmos, bem como processo para preparação da dita composição
GB0320320D0 (en) * 2003-08-29 2003-10-01 Glaxo Group Ltd Novel compounds
GB0321473D0 (en) 2003-09-12 2003-10-15 Glaxo Group Ltd Novel compounds
GB0322510D0 (en) * 2003-09-25 2003-10-29 Glaxo Group Ltd Novel compounds
PT1667975E (pt) * 2003-09-26 2008-02-29 Glaxo Group Ltd Forma polimórfica de 3-fenilsulfonil-8-piperazin-1-il-quinolina
GB0407025D0 (en) * 2004-03-29 2004-04-28 Glaxo Group Ltd Novel compounds
GB0411421D0 (en) * 2004-05-21 2004-06-23 Glaxo Group Ltd Novel compounds
GB0425548D0 (en) * 2004-11-19 2004-12-22 Glaxo Group Ltd Radiolabelled ligands
GB0426313D0 (en) * 2004-12-01 2005-01-05 Merck Sharp & Dohme Therapeutic agents
CA2610456A1 (en) 2005-06-02 2006-12-07 F. Hoffmann-La Roche Ag 3-methanesulfonylquinolines as gaba-b enhancers
CN101228130A (zh) * 2005-07-27 2008-07-23 弗·哈夫曼-拉罗切有限公司 芳氧基喹啉和其作为5-ht6的用途
GB0519765D0 (en) * 2005-09-28 2005-11-09 Glaxo Group Ltd Novel compounds
GB0519758D0 (en) * 2005-09-28 2005-11-09 Glaxo Group Ltd Novel process
GB0519760D0 (en) * 2005-09-28 2005-11-09 Glaxo Group Ltd Novel compounds
EA200801525A1 (ru) * 2005-12-20 2008-10-30 Рихтер Гедеон Нирт. ПРОИЗВОДНЫЕ ХИНОЛИНА, ПРИМЕНИМЫЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ, ОПОСРЕДОВАННЫХ РЕЦЕПТОРАМИ mGluR5
WO2007117413A1 (en) 2006-04-05 2007-10-18 Wyeth Sulfonyl-3-heterocyclylindazole derivatives as 5-hydroxytryptamine-6 ligands
CA2670717C (en) 2007-01-08 2012-01-10 Suven Life Sciences Limited 5-(heterocyclyl)alkyl-n-(arylsulfonyl)indole compounds and their use as 5-ht6 ligands
AU2008225766B2 (en) * 2007-03-15 2012-06-07 Novartis Ag Organic compounds and their uses
US20100041672A1 (en) * 2007-03-21 2010-02-18 Glaxo Group Limited Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome
CA2681030C (en) * 2007-03-23 2015-01-13 Abbott Gmbh & Co. Kg Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
SI2155674T1 (sl) 2007-05-03 2011-10-28 Suven Life Sciences Ltd Aminoalkoksi aril sulfonamid spojine in njih uporaba kot 5-ht6 ligandi
EP2167469B1 (en) * 2007-06-18 2012-08-15 Richter Gedeon Nyrt. Sulfonyl-quinoline derivatives
KR20100039300A (ko) * 2007-08-07 2010-04-15 애보트 게엠베하 운트 콤파니 카게 세로토닌 5-ｈｔ6 수용체의 조절에 반응하는 장애를 치료하는데 적합한 퀴놀린 화합물
MX2010003765A (es) 2007-10-26 2010-04-30 Suven Life Sciences Ltd Compuestos de aminoarilsulfonamida y su uso como ligandos de la 5-hidroxitriptamina6.
EP2254564A1 (en) * 2007-12-12 2010-12-01 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
BRPI0908807A2 (pt) * 2008-02-15 2015-07-28 Hoffmann La Roche Derivados de 3-alquil-piperazina e usos dos mesmos
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
MX2011002884A (es) 2008-09-17 2011-04-21 Suven Life Sciences Ltd Compuestos de aril-sulfonamida-amina y su uso como ligandos de 5-ht6.
WO2010032257A1 (en) 2008-09-17 2010-03-25 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-ht6 ligands
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
SG177434A1 (en) 2009-06-29 2012-02-28 Agios Pharmaceuticals Inc Therapeutic compounds and compositions
LT2522658T (lt) * 2010-01-04 2018-11-26 Nippon Soda Co., Ltd. Heterociklinis junginys, kurio sudėtyje yra azotas, ir žemės ūkio/sodininkystės germicidas
WO2011083487A1 (en) 2010-01-05 2011-07-14 Suven Life Sciences Limited Sulfone compounds as 5-ht6 receptor ligands
RU2443697C1 (ru) * 2010-12-21 2012-02-27 Александр Васильевич Иващенко Замещенные метил-амины, антагонисты серотониновых 5-ht6 рецепторов, способы получения и применения
KR101250606B1 (ko) * 2011-01-24 2013-04-03 이화여자대학교 산학협력단 5-ｈｔ６ 수용체 억제 작용을 갖는 신규한 벤조티아졸 및 벤즈이소티아졸유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
AR086411A1 (es) 2011-05-20 2013-12-11 Nippon Soda Co Compuesto heterociclico conteniendo nitrogeno y fungicida para el uso en agricultura y jardineria
AU2012321345B2 (en) 2011-10-03 2016-03-17 The University Of Utah Research Foundation Application of 5-HT6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
RU2500672C1 (ru) * 2012-10-25 2013-12-10 Андрей Александрович Иващенко (3-арилсульфонилхинолин-8-ил)-диалкил-амины - селективные антагонисты серотониновых 5-ht6 рецепторов, способы их получения и применения
AU2013385618B2 (en) 2013-04-02 2017-01-05 Annji Pharmaceutical Co., Ltd. Multifunctional quinoline derivatives as anti-neurodegenerative agents
US9302992B2 (en) 2013-04-02 2016-04-05 Annji Pharmaceutical Co., Ltd. Multifunctional quinoline derivatives as anti-neurodegenerative agents
US20160324852A1 (en) * 2015-05-07 2016-11-10 Axovant Sciences Ltd. Compositions and methods of treating a neurodegenerative disease
WO2016201373A1 (en) 2015-06-12 2016-12-15 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder
CA2992518A1 (en) 2015-07-15 2017-01-19 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
AR106515A1 (es) 2015-10-29 2018-01-24 Bayer Cropscience Ag Sililfenoxiheterociclos trisustituidos y análogos
JP7027318B2 (ja) * 2016-02-05 2022-03-01 ファーネクスト 神経障害の新規の併用療法
WO2017157929A1 (en) * 2016-03-14 2017-09-21 AbbVie Deutschland GmbH & Co. KG Quinoline compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
CN108290842B (zh) * 2016-05-27 2021-04-06 深圳市塔吉瑞生物医药有限公司 一种取代的喹啉化合物及其药物组合物
WO2018102824A1 (en) * 2016-12-02 2018-06-07 Axovant Sciences Gmbh Methods for treating neurodegenerative disease
KR20210076224A (ko) 2019-12-13 2021-06-24 주식회사 에피바이오텍 퀴놀린 유도체를 포함하는 탈모의 예방 또는 치료용 조성물
KR102281647B1 (ko) * 2020-12-09 2021-07-30 메디케어제약 주식회사 피페라진-퀴놀린 유도체의 제조방법

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US708469A (en) * 1901-08-27 1902-09-02 George Lafayette Caldwell Stroke-regulating mechanism for glass-presses, &c.
JPH02262627A (ja) 1988-12-08 1990-10-25 Japan Synthetic Rubber Co Ltd 有機非線形光学素子
SI9200377A (en) * 1992-12-11 1994-06-30 Krka Process for the preparation of 1-substituted 6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydroquinoline-3-carboxilic acid, novel intermediate used in this process and process for its preparation
GB9300147D0 (en) 1993-01-06 1993-03-03 Minnesota Mining & Mfg Photothermographic materials
GB9311790D0 (en) 1993-06-08 1993-07-28 Minnesota Mining & Mfg Photothermographic materials
US5596001A (en) 1993-10-25 1997-01-21 Pfizer Inc. 4-aryl-3-(heteroarylureido)quinoline derivatves
DK122693D0 (da) 1993-10-29 1993-10-29 Hempels Skibsfarve Fab J C Marin struktur
US5576338A (en) 1995-02-15 1996-11-19 Merck Frosst Canada, Inc. Bis (biaryl) compounds as inhibitors of leukotriene biosynthesis
AUPN842196A0 (en) 1996-03-05 1996-03-28 Fujisawa Pharmaceutical Co., Ltd. New compound
FR2750988B1 (fr) 1996-07-11 1998-09-18 Adir Nouveaux derives de 2-(1h)-quinoleinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20010051719A1 (en) 1996-12-19 2001-12-13 Smithkline Beecham P.L.C. Novel compounds
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
EP0867477B1 (de) 1997-03-25 2002-05-02 Ciba SC Holding AG Polycyclische Verbindungen
DE69818248T2 (de) 1997-04-22 2004-06-17 Janssen Pharmaceutica N.V. Chinolin- und chinazolin-derivate als crf antagonisten
JP2002500675A (ja) 1997-05-28 2002-01-08 アヴェンティス ファーマシューティカルズ プロダクツ インコーポレイテッド 血小板由来成長因子及び／又はｐ５６▲上ｌｃｋ▼チロシンキナーゼを阻害するキノリン及びキノキサリン化合物
US6376670B1 (en) 1997-06-19 2002-04-23 Sepracor Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
HUP0003364A3 (en) 1997-06-19 2002-03-28 Sepracor Inc Marlborough Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6103905A (en) 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6207679B1 (en) 1997-06-19 2001-03-27 Sepracor, Inc. Antimicrobial agents uses and compositions related thereto
EP0994862B1 (en) 1997-07-11 2005-06-01 SmithKline Beecham plc Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
PT930302E (pt) * 1998-01-16 2003-07-31 Hoffmann La Roche Derivados de benzo-sulfona
GB9801392D0 (en) 1998-01-22 1998-03-18 Smithkline Beecham Plc Novel compounds
GB9803411D0 (en) 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
US6100291A (en) 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
US6251893B1 (en) 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
GB9818916D0 (en) 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
GB9819382D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds I
GB9820113D0 (en) 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
US6403808B1 (en) 1999-12-10 2002-06-11 Virginia Commonwealth University Selective 5-HT6 receptor ligands
WO2000042026A1 (en) 1999-01-15 2000-07-20 Novo Nordisk A/S Non-peptide glp-1 agonists
AU4038600A (en) 1999-03-29 2000-10-16 Neurogen Corporation 4-substituted quinoline derivatives as nk-3 and/or gaba(a) receptor ligands
ES2291024T4 (es) * 1999-04-21 2009-03-01 Nps Allelix Corp. Compuestos de piperidina-indol con afinidad con 5-ht6.
WO2000064877A1 (en) 1999-04-26 2000-11-02 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
MY125942A (en) 1999-09-07 2006-09-29 Upjohn Co Aminoalkoxy carbazoles for the treatment of cns diseases
GB9926302D0 (en) 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
WO2001032660A1 (en) 1999-11-05 2001-05-10 Nps Allelix Corp. Compounds having 5-ht6 receptor antagonist activity
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
US6310212B1 (en) 2000-03-28 2001-10-30 Neurogen Corporation 4-substituted quinoline derivatives
PE20020063A1 (es) 2000-06-20 2002-01-30 Upjohn Co Bis-arilsulfonas como ligandos del receptor de 5-ht
SE0002754D0 (sv) 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
GB0021450D0 (en) 2000-08-31 2000-10-18 Smithkline Beecham Plc Novel compounds
US6576644B2 (en) 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
CA2421782A1 (en) 2000-10-02 2002-04-11 Janssen Pharmaceutica N.V. Quinoline and quinolinone derivatives as metabotropic glutamate receptor antagonists
AU9619301A (en) 2000-10-20 2002-04-29 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
EP2298738B1 (en) 2000-11-02 2012-09-19 Wyeth LLC 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
US6849644B2 (en) 2000-11-21 2005-02-01 Smithkline Beecham P.L.C. Isoquinoline derivatives useful in the treatment of CNS disorders
DE60122767T2 (de) 2000-11-24 2007-09-13 Smithkline Beecham P.L.C., Brentford Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
ES2188344B1 (es) 2000-11-29 2004-09-16 Laboratorios Vita, S.A. Compuestos derivados de benzotiofeno, su procedimiento de obtencion y utilizacion de los mismos.
GB0111186D0 (en) 2001-05-08 2001-06-27 Smithkline Beecham Plc Novel compounds
MXPA03011244A (es) 2001-06-07 2004-02-27 Hoffmann La Roche Nuevos derivados de indol con afinidad por el receptor 5-ht6.
CA2450245A1 (en) 2001-06-15 2002-12-27 F. Hoffmann-La Roche Ag 4-piperazinylindole derivatives with 5-ht6 receptor affinity
ITRM20010356A1 (it) 2001-06-21 2002-12-23 Sigma Tau Ind Farmaceuti "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
MXPA04001089A (es) 2001-08-03 2004-05-20 Upjohn Co 5-arilsulfonil indoles que tienen afinidad por el receptor de 5-ht.
EP1414442A1 (en) 2001-08-07 2004-05-06 Smithkline Beecham Plc 3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders
ES2316619T3 (es) 2001-08-10 2009-04-16 F. Hoffmann-La Roche Ag Derivados de arilsulfonilo con afinidad receptora de 5-ht 6.
ES2398434T3 (es) 2001-08-31 2013-03-19 Novartis Ag Isómeros ópticos de un metabolito de iloperidona
SE0103649D0 (sv) 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinoline compounds
US20050176759A1 (en) 2001-12-21 2005-08-11 Mahmood Ahmed 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment cns disorders
US20070270432A1 (en) 2002-02-05 2007-11-22 James Hagan Novel Method
GB0202679D0 (en) 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
ES2260607T3 (es) 2002-02-13 2006-11-01 Glaxo Group Limited Derivados de 7-arilsulfonamido-2,3,4,5-tetrahidro-1h-benzo-diazepina con afinidad por los receptores 5-ht6 para el tratamiento de trastornos del snc.
DE10207844A1 (de) 2002-02-15 2003-09-04 Schering Ag 1-Phenyl-2-heteroaryl-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
EP1478361A2 (en) 2002-02-22 2004-11-24 PHARMACIA & UPJOHN COMPANY Arylsulfone derivatives
US20050124626A1 (en) 2002-03-27 2005-06-09 Johnson Christopher N. Novel compounds
US7452888B2 (en) * 2002-03-27 2008-11-18 Glaxo Group Limited Quinoline derivatives and their use as 5-ht6 ligands
EA009982B1 (ru) 2002-05-13 2008-04-28 Ф. Хоффманн-Ля Рош Аг Производные бензоксазина в качестве модуляторов 5-нт-6, способ их получения, фармацевтические композиции, содержащие эти производные, и их применение
DE10221183A1 (de) 2002-05-13 2003-12-04 Max Planck Gesellschaft Phosphatidyl-oligo-glycerine und Strukturanaloga
MXPA04012122A (es) 2002-06-05 2005-04-19 Hoffmann La Roche Derivados de 1-sulfonil-4-aminoalcoxi indol como moduladores del receptor 5-hidroxitriptamina 6 (5-5-ht6) para tratamiento de trastornos del sistema nervioso central (snc).
US7943639B2 (en) 2002-06-20 2011-05-17 Proximagen Limited Compounds
MXPA04012914A (es) 2002-06-20 2005-03-31 Biovitrum Ab Nuevos compuestos utiles para el tratamiento de la obesidad, diabetes tipo ii y desordenes cns.
EP1587788B9 (en) 2002-09-17 2007-10-24 F. Hoffmann-La Roche Ag 2,7-substituted indoles and their use as 5-ht6 modulators
CN1301970C (zh) 2002-09-17 2007-02-28 弗·哈夫曼-拉罗切有限公司 2,4－取代吲哚和它们作为5－ht6调节剂的用途
CN1309384C (zh) 2002-10-18 2007-04-11 弗·哈夫曼-拉罗切有限公司 具有5－ht6受体亲和性的4－哌嗪基苯磺酰基吲哚
DK1562918T3 (da) 2002-11-08 2008-05-05 Hoffmann La Roche Substituerede benzoxazinoner og anvendelser deraf
DE60316180T2 (de) 2002-12-03 2008-05-29 F. Hoffmann-La Roche Ag Aminoalkoxyindol-derivate als 5-ht6-rezeptorliganden zur bekämpfung von zns-krankheiten
CN100482662C (zh) 2003-02-14 2009-04-29 惠氏公司 作为5-羟基色胺-6配体的杂环基-3-磺酰基氮杂吲哚或-氮杂吲唑衍生物
ATE381334T1 (de) 2003-03-03 2008-01-15 Hoffmann La Roche 2,5-substituiertetetrahydroisochinoline zur verwendung als 5-ht6 modulatoren
TWI289141B (en) 2003-03-11 2007-11-01 Hoffmann La Roche F. Ag. Quinolinone derivatives and uses thereof
GB0305575D0 (en) 2003-03-11 2003-04-16 Glaxo Group Ltd Novel compounds
GB0320320D0 (en) 2003-08-29 2003-10-01 Glaxo Group Ltd Novel compounds
GB0321473D0 (en) 2003-09-12 2003-10-15 Glaxo Group Ltd Novel compounds
GB0322510D0 (en) 2003-09-25 2003-10-29 Glaxo Group Ltd Novel compounds
PT1667975E (pt) 2003-09-26 2008-02-29 Glaxo Group Ltd Forma polimórfica de 3-fenilsulfonil-8-piperazin-1-il-quinolina
GB0407025D0 (en) 2004-03-29 2004-04-28 Glaxo Group Ltd Novel compounds
GB0411421D0 (en) 2004-05-21 2004-06-23 Glaxo Group Ltd Novel compounds
GB0422263D0 (en) 2004-10-07 2004-11-10 Glaxo Group Ltd Novel compounds
GB0519758D0 (en) 2005-09-28 2005-11-09 Glaxo Group Ltd Novel process
GB0519765D0 (en) 2005-09-28 2005-11-09 Glaxo Group Ltd Novel compounds
GB0519760D0 (en) 2005-09-28 2005-11-09 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
DK1956004T3 (da) 2012-08-06
PT1497266E (pt) 2008-09-10
DE60321558D1 (de) 2008-07-24
PT1956004E (pt) 2012-08-31
RU2309154C9 (ru) 2016-09-27
SI1497266T1 (sl) 2008-10-31
EP1956004B1 (en) 2012-06-13
NO329319B1 (no) 2010-09-27
DK1497266T3 (da) 2008-10-06
IL164108A (en) 2010-05-31
AU2003219103B2 (en) 2008-10-23
WO2003080580A3 (en) 2004-02-05
US20110237792A1 (en) 2011-09-29
JP5091913B2 (ja) 2012-12-05
US8236947B2 (en) 2012-08-07
US20050124628A1 (en) 2005-06-09
SI1956004T1 (sl) 2012-09-28
RU2309154C2 (ru) 2007-10-27
WO2003080580A2 (en) 2003-10-02
NZ535239A (en) 2008-03-28
ZA200407320B (en) 2005-11-30
ATE398108T1 (de) 2008-07-15
US20090036682A1 (en) 2009-02-05
IS7470A (is) 2004-09-24
EP1497266A2 (en) 2005-01-19
CA2479786A1 (en) 2003-10-02
RU2004131641A (ru) 2005-06-27
PL374378A1 (en) 2005-10-17
US7799774B2 (en) 2010-09-21
BRPI0308696B1 (pt) 2019-07-16
AU2003219103A1 (en) 2003-10-08
BRPI0308696B8 (pt) 2021-05-25
JP4455064B2 (ja) 2010-04-21
CA2479786C (en) 2011-11-29
KR20040094874A (ko) 2004-11-10
BR0308696A (pt) 2005-01-25
CY1113306T1 (el) 2016-04-13
MXPA04009318A (es) 2005-01-25
TW200403224A (en) 2004-03-01
EP1497266B1 (en) 2008-06-11
CN1315809C (zh) 2007-05-16
BRPI0308696A8 (pt) 2017-04-11
KR101020399B1 (ko) 2011-03-08
AR039127A1 (es) 2005-02-09
EP1956004A1 (en) 2008-08-13
US20100305107A1 (en) 2010-12-02
US7452888B2 (en) 2008-11-18
MY138836A (en) 2009-07-31
JP2005531518A (ja) 2005-10-20
ES2307919T3 (es) 2008-12-01
US7977337B2 (en) 2011-07-12
CN1656075A (zh) 2005-08-17
US20090298841A1 (en) 2009-12-03
IL164108A0 (en) 2005-12-18
JP2009235080A (ja) 2009-10-15
ES2386828T3 (es) 2012-08-31
PL209872B1 (pl) 2011-10-31
HK1074439A1 (en) 2005-11-11
CY1108313T1 (el) 2014-02-12
NO20044588L (no) 2004-10-25
TWI268928B (en) 2006-12-21
US7601837B2 (en) 2009-10-13

Similar Documents

Publication Publication Date Title
IS2599B (is) 3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess
NO2022041I1 (no) Dapagliflozin og farmasøytisk akseptable salter derav - forlenget SPC
IS7948A (is) Fosfónóoxýkínasólínafleiður og lyfjafræileg notkun þeirra
LUC00127I1 (fr) Dacomitinib et ses derives pharmaceutiquement accepatbles ( vizimpro )
LU92517I2 (fr) Delamanide et ses dérivés pharmaceutiquement acceptables
NO20041975D0 (no) Bicyklisk oksopyridin og oksopyrimidinderivater
IS6385A (is) Ný notkun og nýjar N-asabísýkló-amíð afleiður
ATE390426T1 (de) Aminocyclische substituierte pyrrolopyrimidinderivate und pyrrolopyridinderivate
LU92513I2 (fr) Sofosbuvir et ses dérivés pharmaceutiquement acceptables (solvaldi)
ATE478870T1 (de) Spiroindolinpiperidinderivate
ATE460418T1 (de) Heterocyclocarboxamidderivate
DE60330372D1 (de) Indol-3-schwefelderivate
ATE467631T1 (de) Chinuclidinamidderivate
IS7720A (is) Píperidín-N-oxíð-afleiður
DK2248807T3 (da) N-Phenyl-2-pyrimidinaminderivater
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
NO20052524D0 (no) Aminerte isofiavonoidderivater og anvendelse derav
DK1513836T3 (da) Piperazinylacylpiperidinderivater, fremstilling og terapeutisk anvendelse heraf
DK1590321T3 (da) Arylalkylcarbamat-derivater, fremstilling og terapeutisk anvendelse deraf
ATE335729T1 (de) 3h-chinazoline -4-on derivaten
DK1556382T3 (da) 3-Phenylpyridoindolderivater, fremstilling og terapeutisk anvendelse deraf
ATE423771T1 (de) Tetrahydrochinolinderivate
DE50306277D1 (de) 4-alkyl-/4-alkenyl-/4-alkinylmethyl/-1-arylcyclohexylamin-derivate
DK1392670T3 (da) Substituerede C-furan-2-yl-methylamin- og C-thiophen-2-yl-methylamin-derivater
EP1499338A4 (en) 7-HYDROXY-16ALPHA-FLUORO-5-ANDROSENES-17-ONE AND 7-HYDROXY-16ALPHA-FLUORO-5-ANDROSTAN-17-ONE AND THEIR DERIVATIVES